Novo Nordisk Announces Launch of New Factor VIII Therapy
Novo Nordisk has announced the launch of ESPEROCT®, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A. The new therapy is specifically indicated for routine…
Description and Management of Pain and Functional Impairment in US Adults With Hemophilia: Initial Observations From the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study
Objective: Hemophilia is marked by frequent joint bleeding, resulting in acute and chronic pain and functional impairment. Surveys in US adults with hemophilia demonstrate suboptimal pain management and quality of life (QoL). The…
NHF Awarded 4-star Rating from Charity Navigator
For the 10th consecutive year, the National Hemophilia Foundation (NHF) has attained the prestigious 4-star rating from Charity Navigator, the largest independent charity evaluator in the US. “Only two percent of the charities we evaluate have…
NHF, WFH, EHC Monitor Coronavirus Impact on Bleeding Disorders Community
The National Hemophilia Foundation (NHF) has been monitoring the latest information on the current coronavirus (2019-nCoV) as it pertains to the bleeding disorders community. The Plasma Protein Therapeutics Association (PPTA) has issued a…
FDA Releases Guidance Documents for Gene Therapies
The U.S. Food and Drug Administration (FDA) has released several new gene therapy guidance documents to provide “regulatory clarity” for developers of the many investigational therapies designed to treat any number of chronic conditions, including…
NHF Urges Congressional Action on The Hemophilia SNF Access Act
The National Hemophilia Foundation is pleased to endorse The Hemophilia SNF Access Act, critical legislation that will rectify a long-standing problem of Medicare beneficiaries with hemophilia and other bleeding disorders being able to access…
NHF and HFA Hold Safety Summit
The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) convened a Safety Summit in Washington, DC, on January 29-30th, 2020, to discuss monitoring, educating and communicating issues around bleeding disorders product…
NHF and the Green Park Collaborative Launch Project to Measure Mental Health Outlook
Baltimore, MD (January 28, 2020) – The Green Park Collaborative (GPC) is partnering with the National Hemophilia Foundation (NHF) to develop a publicly available, content-validated, patient-reported outcome measure (PROM) that…
Study Looks at Postpartum Hemorrhage in Type 3 VWD
Newly published results from a literature review-based study suggest that primary postpartum hemorrhage (PPH) is a persistent clinical challenge in patients with type 3 von Willebrand disease (VWD), even in those who received their diagnosis before…
National Hemophilia Foundation Announces Next CEO
NEW YORK (January 17, 2020) – The Board of Directors of the National Hemophilia Foundation (NHF) today announced that Dr. Leonard A. Valentino will be the foundation’s next Chief Executive Officer. Dr. Valentino…